Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers

Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case–control study

Breast Cancer Research and Treatment, 02/02/2016

This study suggest that a short course of HRT should not be contra–indicated for BRCA1 mutation carriers who have undergone menopause and who have no personal history of cancer.

Methods

  • The researchers conducted a case–control analysis of 432 matched pairs of women with a BRCA1 mutation.
  • Detailed information on HRT use after menopause (duration, type, age at first/last use, formulation) was obtained from a research questionnaire administered at the time of study enrollment.
  • Conditional logistic regression was used to estimate the odds ratio (OR) and 95 % confidence intervals (CI) associated with HRT use.

Results

  • The mean duration of HRT use after menopause was 4.3 years among the cases and 4.4 years among the controls (P = 0.83).
  • The adjusted OR for breast cancer comparing all women who ever used HRT to those who never used HRT was 0.80 (95 % CI 0.55–1.16; P = 0.24).
  • Findings did not differ by type of menopause (natural vs. surgical), by recency of use, by duration of use, and by formulation type.

About Dr Colin Holloway

Gp interested in natural hormone treatment for men and women of all ages

Posted on August 4, 2016, in Uncategorized. Bookmark the permalink. Leave a comment.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: